

HYDRALAZINE

PRESENTATION: Ampoules containing 20mg powder hydralazine hydrochloride for reconstitution.

INDICATION: Hypertension.

DOSE AND ADMINISTRATION: Initial rate is 200-300 micrograms/minute; 12-18mls/hour. Titrated to individual blood pressure but maintenance rate usually within range of 50-150micrograms/minute; 3-9mls/hour.

ICU STANDARD INFUSION

Reconstitute three 20mg vials of hydralazine, each with 1ml water for injections. Further dilute the 60mg (3ml) to 60ml with sodium chloride 0.9%.

CONCENTRATION: 1mg/ml

STABILITY: Physically and chemically stable for 12 hours at room temperature.

ADDITIONAL NOTES: Hydralazine is not stable in glucose 5%.

References:

1. Hydralazine. Advanz Pharma. Summary of Product Characteristics. www.emc.medicines.ork.uk Updated 08/08/22. Accessed 25/10/22.
2. Dade J et al. UKCPA Critical Care Group. Minimum infusion volumes for fluid restricted critically ill patients. 4th Ed. V4 2012. Accessed 25/10/22.
3. Hydralazine. Version 6. The UK Injectable Medicines Guide. Adapted for use in NHS Lothian. Accessed 25/10/22.

Title: Hydralazine	
ID:	Authors: Claire Hannah
Category:	Document Version: 3.0
Status Draft/Final: Final	Review Date: October 24
Authoriser: Lothian Critical Care QIT Editorial Board.	Authorisation Date: October 22
Date added to Intranet: 04/11/22	
Key Words	
Comments	